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SUMMARY
Introduction In spite of the growing number of reports on the study of anti-nucleosome and anti-C1q 
antibodies, there are still controversies on their significance as disease activity markers in patients with 
systemic lupus erythematosus (SLE) and their use in everyday clinical practice.
Objective Our aim was to assess the presence of anti-dsDNA, anti-nucleosome and anti-C1q antibodies 
in SLE patients, as well as to establish their sensitivity, specificity, positive and negative predictive value, 
and their correlation with SLE and lupus nephritis clinical activity.
Methods The study enrolled 85 patients aged 45.3±9.7 years on the average, with SLE of average dura-
tion 10.37±7.99 years, hospitalized at the Institute „Niška Banja“ during 2011, and 30 healthy individuals 
as controls. Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI). In all examinees the levels of anti-dsDNA, anti-nucleosome and anti-C1q antibodies were meas-
ured using the ELISA method with Alegria Test Strips Orgentec (Germany).
Results Patients with active lupus nephritis had a higher presence of anti-C1q antibodies and higher 
co-positivity of anti-dsDNA, anti-nucleosome, and anti-C1q antibodies compared to those with inactive 
lupus nephritis (77.77% vs. 21.74%; p<0.01). SLE patients with SLEDAI ≥11 had a higher presence of anti-
nucleosome (93.75% vs. 64.15%; p<0.01) and anti-C1q antibodies (46.87% vs. 22.64%; p<0.05), as well as 
a higher mean level of anti-nucleosome antibodies (107.79±83.46 U/ml vs. 57.81±63.15 U/ml; p<0.05), 
compared to those with SLEDAI of 0-10. There was a positive correlation between the SLEDAI and the level 
of anti-dsDNA (r=0.290; p<0.01), anti-nucleosome (r=0.443; p<0.001), and anti-C1q antibodies (r=0.382; 
p<0.001). Only anti-C1q antibodies demonstrated correlation with proteinuria (r=0.445; p<0.001).
Conclusion Anti-nucleosome and anti-C1q antibodies demonstrated association with SLE and lupus 
nephritis activity, suggesting their potential usefulness in making predictions about lupus nephritis and 
assessment of disease activity.
Keywords: systemic lupus erythematosus; anti-dsDNA antibodies; anti-nucleosome antibodies; anti-C1q 
antibodies; lupus nephritis; SLEDAI
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chron-
ic inflammatory autoimmune disease charac-
terized by multisystem clinical presentation 
and serologic findings of various antibodies 
[1, 2]. It has been shown that conventional pa-
rameters such as anti-dsDNA antibodies, com-
plement level, proteinuria, creatinine clearance 
and urine sediment are not specific enough to 
detect disease activity in renal involvement and 
nephritis relapse [3]. In recent years, new bi-
omarkers have been intensely studied, which 
could mark renal involvement before clinical 
manifestations, i.e. indicate subclinical dis-
ease forms. Among them, a significant place 
is reserved for anti-nucleosome [4, 5, 6] and 
anti-C1q antibodies [7, 8, 9], which have been 
extensively studied. Anti-nucleosome antibod-
ies are highly correlated with anti-dsDNA anti-
bodies and are considered sensitive SLE mark-
ers, but their correlation with disease activity 
and renal involvement remains controversial. 
There are opinions that anti-C1q surveillance 
would be important in the clinical monitor-
ing of SLE patients, as a non-invasive biologic 
marker of renal involvement, both for early 
detection of nephritis and for prediction of 
exacerbations [10-14]. In some reports, the au-
thors have stated that anti-dsDNA antibodies 
are necessary but not sufficient for the develop-
ment of lupus nephritis exacerbations, and that 
anti-dsDNA antibodies and anti-nucleosome 
antibodies, with elevated levels of anti-C1q 
antibodies, are associated with renal disease 
[15, 16, 17].
In spite of a growing number of reports on 
the study of anti-nucleosome and anti-C1q an-
tibodies, there are still controversies regarding 
their significance as disease activity markers in 
SLE patients and their use in everyday clinical 
practice.
OBJECTIVE
Our aim in this study was to examine the pres-
ence of anti-dsDNA, anti-nucleosome and anti-
C1q antibodies in SLE patients, and to establish 
their sensitivity, specificity, and positive and   
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negative predictive value. We also attempted to establish 
their possible association with clinical activity of SLE and 
lupus nephritis activity.
METHODS
The study enrolled 85 patients with SLE, hospitalized at 
the Clinic of Rheumatology of the Institute „Niška Banja“ 
in 2011, in whom the diagnosis was made based on the 
criteria of the American College of Rheumatology revised 
in 1997. Thirty healthy individuals made up the control 
group. The study was also performed at the Center of 
Medical Biochemistry of the Clinical Centre in Niš. All 
patients were carefully considered and examined using the 
same methodology. Prior to inclusion, all patients were 
first informed about study aims, signing after that the in-
formed consent to be enrolled in the study. The Ethics 
Committee of the Faculty of Medicine in Niš also gave 
their consent for the study to be carried out. Inclusion 
criteria for the study were as follows: age above 18, defini-
tive diagnosis of SLE, made according to the criteria of the 
American College of Rheumatology revised in 1997, with 
present at least 4 of 11 criteria in total.
In addition to clinical examination and supplemental 
diagnostic methods, disease activity was assessed in all 
patients using Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI), based on a standardized ques-
tionnaire. The SLEDAI evaluates the activity of 9 organ 
systems based on the presence or absence of 24 variables 
during the examination. The value range was 0-105. Based 
on the total sum, the disease was classified as follows: with-
out activity 0, low activity 1-5, moderate activity 6-10, high 
activity 11-19, and very high activity ≥20. The examinees 
were divided into 2 groups; the first group consisted of 
those without disease activity, with low or moderate activ-
ity (SLEDAI 0-10), and the second consisted of those with 
high and very high disease activity (SLEDAI ≥11).
Involvement of different organs and systems was de-
termined in accordance to the current criteria. For the 
diagnosis of lupus nephritis, the presence of proteinuria 
0.5 g/24h was necessary, and/or the finding of pathologic 
urine sediment. Glomerular filtration assessment was per-
formed in all examinees using the Modification of Diet 
Renal Disease (MDRD) formula.
Simultaneously with clinical examination and disease 
activity assessment, the samples of blood were taken and 
centrifuged, and serum samples were frozen at -70°C up 
to the moment of determination of the studied antibodies. 
In addition to the standard lab and immunologic analy-
ses, the levels of anti-dsDNA, anti-nucleosome antibodies, 
and anti-C1q antibodies were measured in SLE patients 
and controls. The presence of these antibodies was de-
termined using the ELISA test on the automatic ELISA 
reader Alegria (Organtec, Germany). Autoantibodies were 
determined on the Alegria Test Strips (Organtec, Germa-
ny), barcoded per each antibody, using the technique of 
indirect immunologic reaction. The Anti-C1q ELISA is a 
test for the quantitative detection of class IgG antibodies 
against the C1q complement component. Positivity cut-
offs for the examined antibodies were set in compliance 
with the manufacturer’s instructions, being ≥25 U/ml for 
anti-dsDNA, ≥20 U/ml for anti-nucleosome, and ≥10 U/
ml for anti-C1q antibodies. Maximal possible antibody 
values were 200 U/ml for anti-dsDNA, 200 U/ml for anti-
nucleosome, and 100 U/ml for anti-C1q antibodies. The 
assays were performed at the Center of Medical Biochem-
istry, Clinical Center Niš.
The Sigmastat 3.5 program was used for statistical data 
processing. The following tests were employed: descriptive 
statistics, Student’s t-test, Mann-Whitney test, and Chi-
square test.
RESULTS
Average age of SLE patients was 45.3±9.7 years. Average 
age of control group examinees was 44.7±9.5 years. There 
were 78 (91.77%) women and 7 (8.23%) men in the SLE 
group, and among controls there were 27 (90%) women 
and 3 (10%) men. Both groups were homogenous related 
to age. Average disease duration in the studied group was 
10.37±7.99 years (from 1 month, to 29 years), and average 
age at diagnosis was 35.88±9.66 years. The median for the 
number of diagnostic criteria was 5 (minimum 4, maxi-
mum 9). The frequency of individual clinical manifesta-
tions at the time of examination was for arthritis/arthral-
gias 69.41%, skin changes 65.88%, serositis 24.70%, hema-
tologic manifestations 24.70%, lupus nephritis 37.56%, and 
neuropsychic manifestations 18.82%. Out of 32 patients 
with lupus nephritis, 9 (28.12%) had active nephritis, and 
23 (71.88%) inactive lupus nephritis; 53 (62.35%) patients 
had SLEDAI from 0 to 10, and 32 (37.65%) had SLEDAI 
score ≥11. The average SLEDAI value in all SLE patients 
was 11.38±7.55.
Positive anti-dsDNA antibodies were found in 59 
(69.41%) patients, anti-nucleosome antibodies in 64 
(75.29%), and anti-C1q antibodies in 27 (31.76%) SLE pa-
tients (Table 1). All control group subjects were negative 
for antibodies. There were no significant differences in the 
positivity of studied antibodies between the groups with 
and without nephritis. Moreover, there were no differences 
in the simultaneous positivity of all three antibodies, and 
simultaneous positivity of two antibodies between nephritis 
Table 1. Frequency of positive anti-dsDNA, anti-nucleosome and anti-
C1q in SLE patients
Antibodies SLE
(n=85; 100%)
LN
(n=32; 37.64%)
SLE without LN
(n=53; 62.36%)
Anti-dsDNA 59 (69.41%) 26 (81.25%) 33 (62.26%)
Anti-
nucleosome 64 (75.29%) 26 (81.25%) 38 (71.70%)
Anti-C1q 27 (31.76%) 12 (37.50%) 15 (28.30%)
Anti-dsDNA, 
C1q, Nucl. 24 (28.23%) 12 (37.50%) 12 (22.64%)
Anti-dsDNA, 
Nucl. 25 (29.41%) 11 (34.37%) 14 (26.41%)
Anti-C1q, Nucl. 2 (2.35%) - 2 (3.77%)
SLE – systemic lupus erythematosus; LN – lupus nephritis; n – number of patients     
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and nephritis-free groups (Table 1). When we compared 
the positivity of studied antibodies between the groups of 
patients with active and inactive lupus nephritis, we found a 
significant difference in anti-C1q positivity and simultane-
ous positivity of all three antibodies, with positive anti-C1q 
antibodies and co-positive anti-dsDNA, anti-nucleosome, 
and anti-C1q antibodies found in 5 out of 23 (21.74%) 
patients with inactive lupus nephritis and in 7 out of 9 
(77.77%) patients with active lupus nephritis (p<0.01). In 
the group with active lupus nephritis, 100% patients had 
positive anti-nucleosome antibodies (Table 2).
Specificity and sensitivity of the studied antibodies was 
100% and 87.06% for anti-dsDNA antibodies for the cut-
off >10.6 U/ml, 96.67% and 82.35% for anti-nucleosome 
antibodies for the cut-off >9.7 U/ml, and 100% and 35.71% 
for anti-C1q antibodies for the cut-off >9.4 U/ml (Graph 
1, Table 3). Positive and negative predictive value for SLE 
diagnosis was 100% and 74.10% for anti-dsDNA antibod-
ies, 98.59% and 65.92% for anti-nucleosome antibodies, 
and 100% and 35.50% for anti-C1q antibodies.
Examining antibody positivity in the group with ac-
tive and very active disease (SLEDAI ≥11), compared to 
those with SLEDAI from 0 to 10, we found a significant 
difference in anti-nucleosome and anti-C1q antibodies 
(Table 4).
The mean level of anti-dsDNA antibodies in the SLE 
group was significantly higher – 80.18±74.69 U/ml, com-
pared to controls with 5.97±3.02 U/ml (p<0.001). In the 
SLE group, the mean level of anti-nucleosome antibod-
ies was 74.38±74.16 U/ml, which was significantly higher 
than in controls with 6.37±3.01 U/ml (p<0.001). The mean 
level of anti-C1q in SLE patients was 14.67±23.60 U/ml, 
and in controls it was 4.29±1.99 U/ml, although without 
any significant difference.
Examination of the mean levels of antibodies in those 
with lupus nephritis and those without it did not reveal 
significant differences for any of the antibodies. In the 
group with active lupus nephritis, mean levels of all three 
antibodies were significantly higher compared to those 
with inactive lupus nephritis (Table 5).
Table 2. Frequency of positive anti-dsDNA, anti-nucleosome and anti 
C1q antibodies in SLE patients according to lupus nephritis (LN) activity
Antibodies
LN (n=32; 37.64%)
SLE without LN
(n=53; 62.36%) Active
(n=9; 28.12%)
Inactive
(n=23; 71.87%)
Anti-dsDNA 8 (88.88%) 18 (78.26%) 33 (62.26%)
Anti-
nukleosome 9 (100.00%) 17 (73.91%) 38 (71.70%)
Anti-C1q 7 (77.77%) 5 (21.74%)a 15 (28.30%)b
Anti-DNA, C1q, 
Nucl. 7 (77.77%) 5 (21.74%)c 12 (22.64%)d
Anti-DNA, Nucl. 1 (11.11%) 10 (43.48%) 14 (26.41%)
Anti-C1q, Nucl. 2 (3.77%)
* p<0.01 vs. Active (a – χ2=8.67; b – χ2=7.46; c – χ2=8.67; d – χ2=9.04)
Table 3. Specificity and sensitivity of anti-dsDNA, anti-nucleosome, and anti-C1q antibodies
Antibodies AUC SE 95% CI Specificity Sensitivity Criterion
Anti-dsDNA 0.934* 0.022 0.871-0.972 100.00 87.06 >10.6
Anti-nucleosome 0.916* 0.025 0.849-0.960 96.67 82.35 >9.7
Anti-C1q 0.621 0.057 0.526-0.710 100.00 35.71 >9.4
* p<0.001 vs. C1q
AUC – area under the curve; SE – statistical error; CI – confidence interval
Graph 1. Receiver operating characteristic curve for anti-dsDNA, anti-
nucleosome, and anti C1q antibodies (ab). Specificity and sensitivity 
of the studied antibodies was 100% and 87.06% for anti-dsDNA ab, 
96.67% and 82.35% for anti-nucleosome ab and 100% and 35.71% 
for anti-C1q ab.
Table 4. Frequency of positive anti-dsDNA, anti-nucleosome and anti-
C1q in SLE patients according to SLEDAI values
Antibodies
SLEDAI SLEDAI 
11.38±7.55
(n=85; 100.00%)
0–10
(n=53; 62.35%)
≥11
(n=32; 37.64%)
Anti-DNA 36 (67.92%) 23 (71.87%) 59(69.41%)
Anti-
nucleosome 34 (64.15%) 30 (93.75%)* 64 (75.29%)**
Anti-C1q 12 (22.64%) 15 (46.87%)*** 27 (31.76%)
Anti-DNA, 
C1q, Nucl. 12 (22.64%) 12 (37.50%) 24 (28.23%)
Anti-DNA, 
Nucl. 16 (30.18%) 9 (28.12%) 25 (29.41%)
Anti-C1q, Nucl. 1 (1.88%) 1(3.12%) 2 (2.35%)
* p<0.01 (χ2=8.52) vs. SLEDAI=0–10;
** p<0.05 (χ2=5.01) vs. SLEDAI≥11;
*** p<0.05 (χ2=4.51) vs. SLEDAI=0–10
SLEDAI – Systemic Lupus Erythematosus Disease Activity Index
Table 5. Mean levels of anti-dsDNA, anti-nucleosome and anti-C1q in 
the group with active and inactive lupus nephritis (LN)
Antibodies
LN (n=32; 37.64%)
LN
(n=32; 37.64%) Active
(n=9; 28.12%)
Inactive
(n=23; 71.87%)
Anti-dsDNA 144.04±75.19 61.59±57.66* 84.78±72.37
Anti-
nucleosome
176.59±44.44 39.17±34.10*** 77.82±72.63**
Anti-C1q 34.78±39.89 7.87±7.13* 15.44±24.45
* p<0.05 vs. Active; ** p<0.01 vs. Active; *** p<0.001 vs. Active  
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The mean levels of studied antibodies were higher 
in the groups with high and very high disease activity 
(SLEDAI≥11) compared to the group without disease 
activity, with low and moderate activity (SLEDAI from 
0 to 10), but the difference was significant only for anti-
nucleosome antibodies (Table 6).
Examining the correlation between the antibodies and 
SLEDAI-assessed disease activity, we found a positive cor-
relation for all three antibody types. There was a positive 
correlation between anti-dsDNA antibodies and SLEDAI 
(r=0.290; p<0.01) (Graph 2). We also found a positive cor-
relation between anti-nucleosome antibodies and SLEDAI 
(r=0.443; p<0.001) (Graph 3), as well as between anti-C1q 
antibodies and SLEDAI (r=0.382; p<0.001) (Graph 4).
Examining the intercorrelation between these antibod-
ies the following positive correlations were found: be-
tween anti-dsDNA and antinucleosome antibodies it was 
r=0.561 (p<0.001), between anti-dsDNA and anti-C1q it 
was r=0.403 (p<0.001), and between anti-nucleosome and 
anti-C1q antibodies it was r=0.436 (p<0.001). All three 
antibodies demonstrated negative correlations with C3 
complement component, which were r=-0.345 (p<0.01) for 
anti-dsDNA; r=-0.450 (p<0.001) for anti-nucleosome an-
tibodies; and r=-0.300 ( p<0.001) for anti-C1q antibodies.
When the renal function parameters were examined 
(proteinuria and glomerular filtration assessed using the 
MDRD formula), out of all three studied parameters only 
anti-C1q antibodies demonstrated a correlation with pro-
teinuria (r=0.445; p<0.001). There was no correlation be-
tween the examined antibodies and glomerular filtration.
DISCUSSION
Studies have shown that anti-nucleosome antibodies are 
present in 70-100% of SLE patients, and that they dem-
onstrate a high specificity (up to 97%) [4, 5, 18], which 
agrees with our own results (96.67%). Anti-C1q antibodies 
have been identified in 30-60% of SLE patients [16], which 
agrees with our findings (31.76%). Bizzaro et al. [19] have 
recently published the results of their meta-analysis of 26 
studies, comparing the sensitivity, specificity, positive and 
negative predictive value of anti-dsDNA and anti-nucle-
osome antibodies. The comparative analysis showed that 
anti-nucleosome antibodies had higher diagnostic sensi-
tivity (59.9% vs. 52.4%), with specificity slightly higher 
than anti-dsDNA antibodies (94.9% vs. 94.2%). In the past 
studies of juvenile SLE, specificity and positive predictive 
value for anti-nucleosome antibodies were 96-98%, and 
specificity for anti-C1q was 92-100% [20].
Our results demonstrated that anti-dsDNA and anti-
nucleosome had high specificity and positive predictive 
value for the SLE diagnosis. These results agree with the 
results published for adults with SLE and for juvenile SLE, 
so that all three antibody types can be considered reliable 
markers in the SLE diagnosis [4, 5, 8, 18]. In addition to 
the reports on the high specificity of anti-C1q antibodies 
in SLE diagnosis [20], as in our study, there have been 
many studies suggesting that anti-C1q antibodies are not  Graph 4. Positive correlation between SLEDAI and anti-C1q ab levels
Table 6. Mean levels of anti-dsDNA, anti-nucleosome and anti-C1q in 
the groups with SLEDAI from 0-10 and SLEDAI ≥11
Antibodies
SLEDAI SLE
11.38±7.55
(n=85; 
100.00%)
0–10
(n=53; 62.35%)
≥11
(n=32; 37.64%)
Anti-dsDNA 71.57±71.33 96.54±77.61 80.18±74.69
Anti-
nucleosome 57.81±63.15 107.79±83.46* 74.38±74.16
Anti-C1q 10.07±15.89 22.12±31.56 14.67±23.60
* p<0.05 vs. SLEDAI=0-10 
Graph 2. Positive correlation between Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) and anti-dsDNA ab levels
Graph 3. Positive correlation between SLEDAI and anti-nucleosome 
ab levels
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specific for SLE and that they can be encountered in other 
autoimmune (Sjögren’s syndrome, hypocomplementemic 
urticarial vasculitis) and infectious diseases [21]. The 
prevalence of anti-C1q antibodies in healthy population 
ranges from 2% to 8%. Our result about high specificity 
of anti-C1q antibodies in SLE diagnosis can be explained 
by the fact that there were few healthy controls (n=30) and 
that all of them had negative anti-C1q antibodies for the 
cut-off >9.4 U/ml.
In our study, although the prevalence of positive find-
ings of anti-nucleosome antibodies was higher compared 
to anti-dsDNA antibodies (75.29% vs. 69.41%), the sensi-
tivity of anti-nucleosome antibodies for the diagnosis of 
SLE was lower compared to the sensitivity of anti-dsDNA 
antibodies (82.35% vs. 87.06%). This can be explained by 
the fact that in our study antibody positivity cut-off values 
according to the ROC curve were lower than that recom-
mended by the ELISA test manufacturer, and were >10.6 
U/ml for anti-dsDNA antibodies, and >9.7 U/ml for anti-
nucleosome antibodies.
Anti-nucleosome [6, 22-27] and anti-C1q antibodies [7, 
10, 11] have been described as indicators of disease activ-
ity and lupus nephritis activity in adults, which agrees with 
our results. There have been reports about anti-nucleosome 
antibodies being a sensitive marker of renal involvement in 
the absence of anti-dsDNA antibodies [25, 28]. Katsumata 
et al. [29] have demonstrated the association of anti-C1q 
antibodies with global SLE activity, but not with active lu-
pus nephritis. Recently, Tan et al. [30] have reported that in 
281 SLE patients with lupus nephritis anti-C1q antibodies 
have been closely associated with C1q concentrations and 
glomerular C1q deposition, concluding that the kidney is 
certainly one of the target organs of C1q antibodies.
Our results demonstrated that the presence of anti-C1q 
with simultaneous presence of all three antibody types was 
significantly higher in the group with active compared to 
the group with inactive lupus nephritis. Simultaneous 
positivity of anti-dsDNA, anti-nucleosome, and anti-C1q 
antibodies can be a marker of active lupus nephritis. Sui 
et al. [31] have recently reported their results concern-
ing a powerful association of simultaneous positivity of 
anti-dsDNA, anti-nucleosome, and anti-histone antibodies 
with lupus nephritis activity, especially with proliferative 
glomerulonephritis.
We demonstrated a high sensitivity of both anti-dsDNA 
and anti-nucleosome antibodies. Although anti-C1q an-
tibodies had a low level of sensitivity, our results showed 
them to be a good marker of lupus nephritis activity, being 
the only ones that correlated with proteinuria, which was 
in accordance with the results of Akhter et al. [32].
Similar to the results of some studies [4, 6, 8, 11], our 
results showed a correlation of anti-dsDNA, anti-nucleo-
some, and anti-C1q antibodies with the SLEDAI activity 
index. Meyer et al. [7] have shown that anti-C1q can be 
a good serologic marker of the subsequent development 
of active proliferative glomerulonephritis in SLE patients, 
and that patients without anti-C1q are exposed to a very 
low risk of developing severe proliferative glomerulone-
phritis forms. Similar results have been reported by Chen 
et al. [11], concluding that anti-C1q antibodies are a non-
invasive biologic marker in the prediction of lupus ne-
phritis histopathology, and that low titers or absence of 
anti-C1q antibodies may have an impact on therapeutic 
decision-making in SLE. The same authors have found 
positive intercorrelations between anti-dsDNA, anti-nu-
cleosome, and anti-C1q, as well as their negative correla-
tion with C3 complement component, which agrees with 
our own findings.
CONCLUSION
Anti-nucleosome and anti-C1q antibodies demonstrated 
an association with SLE and lupus nephritis activity, sug-
gesting their potential usefulness in making predictions 
about lupus nephritis and assessment of disease activity.
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КРАТАК САДРЖАЈ
Увод Упр  кос број  ним са  оп  ште  њи  ма о ис  пи  ти  ва  њу ан  ти  ну-
кле  о  зом  ских и ан  ти-C1q ан  ти  те  ла, и да  нас по  сто  је опреч  на 
ми  шље  ња о њи  хо  вом зна  ча  ју као по  ка  за  те  љи  ма ак  тив  но-
сти бо  ле  сти код осо  ба са си  стем  ским ери  тем  ским лу  пу  сом 
(СЕЛ) и њи  хо  вој при  ме  ни у сва  ко  днев  ној кли  нич  кој прак  си.
Циљ ра  да Циљ ра  да је био да се ис  пи  та по  сто  ја  ње ан  ти-
dsDNA, ан  ти  ну  кле  о  зом  ских и ан  ти-C1q ан  ти  те  ла код бо  ле-
сни  ка са СЕЛ, утвр  де њи  хо  ва сен  зи  тив  ност, спе  ци  фич  ност, 
по  зи  тив  на и не  га  тив  на пре  дик  тив  на вред  ност и уста  но  ви 
њи  хо  ва ко  ре  ла  ци  ја с кли  нич  ком ак  тив  но  шћу СЕЛ и ак  тив-
но  шћу лу  пу  сног не  фри  ти  са (ЛН).
Ме  то  де ра  да Ис  тра  жи  ва  ње је об  у  хва  ти  ло 85 бо  ле  сни  ка са 
СЕЛ, про  сеч  не ста  ро  сти од 45,3±9,7 го  ди  на и про  сеч  ног тра-
ја  ња бо  ле  сти од 10,37±7,99 го  ди  на, ко  ји су бол  нич  ки ле  че  ни 
2011. го  ди  не у Ин  сти  ту  ту за ле  че  ње и ре  ха  би  ли  та  ци  ју „Ни-
шка Ба  ња“, и 30 здра  вих осо  ба ко  је су чи  ни  ле кон  трол  ну гру-
пу. Ак  тив  ност бо  ле  сти је про  це  ње  на ко  ри  шће  њем Syste­mic­
Lu­pus­Erythe­ma­to­sus­Di­se­a­se­Ac­ti­vity­In­dex (SLE­DAI). Код свих 
ис  пи  та  ни  ка је ме  то  дом ELI­SA ме  рен ни  во ан  ти-dsDNA, ан  ти-
ну  кле  о  зом  ских и ан  ти-C1q ан  ти  те  ла ко  ри  шће  њем тест-тра  ка 
Ale­gria® (OR­GEN­TEC, Не  мач  ка).
Ре  зул  та  ти Код бо  ле  сни  ка с ак  тив  ним ЛН за  бе  ле  же  ни су ве-
ће при  су  ство ан  ти-C1q ан  ти  те  ла и ве  ћа исто  вре  ме  на по  зи-
тив  ност ан  ти-dsDNA, ан  ти  ну  кле  о  зом  ских и ан  ти-C1q ан  ти  те-
ла у од  но  су на гру  пу с не  ак  тив  ним ЛН (77,77% пре  ма 21,74%; 
p<0,01). Код бо  ле  сни  ка са СЕЛ и вред  но  шћу SLE­DAI 11 и ве-
ћом уста  но  вље  но је ве  ће при  су  ство ан  ти  ну  кле  о  зом  ских 
(93,75% пре  ма 64,15%; p<0,01) и ан  ти-C1q ан  ти  те  ла (46,87% 
пре  ма 22,64%; p<0,05), као и ви  ши сред  њи ни  во ан  ти  ну  кле  о-
зом  ских ан  ти  те  ла (107,79±83,46 U/ml пре  ма 57,81±63,15 U/ml; 
p<0,05) у од  но  су на бо  ле  сни  ке с вред  но  шћу SLE­DAI од 0 до 
10. Утвр  ђе  на је по  зи  тив  на ко  ре  ла  ци  ја из  ме  ђу SLE­DAI и ни  воа 
ан  ти-dsDNA (r=0,290; p<0,01), ан  ти  ну  кле  о  зом  ских (r=0,443; 
p<0,001) и ан  ти-C1q ан  ти  те  ла (r=0,382; p<0,001). Ан  ти-C1q 
ан  ти  те  ла су је  ди  на по  ка  за  ла ко  ре  ла  ци  ју с про  те  и  ну  ри  јом 
(r=0,445; p<0,001).
За  кљу  чак Ан  ти  ну  кле  о  зом  ска и ан  ти-C1q ан  ти  те  ла по  ка  зу-
ју удру  же  ност с ак  тив  но  шћу СЕЛ и ЛН, а од  ре  ђи  ва  ње ових 
ан  ти  те  ла мо  же би  ти ко  ри  сно за пред  ви  ђа  ње раз  во  ја ЛН и 
про  це  ну ак  тив  но  сти бо  ле  сти.
Кључ  не ре  чи: си  стем  ски ери  тем  ски лу  пус; ан  ти-dsDNA ан-
ти  те  ла; ан  ти  ну  кле  о  зом  ска ан  ти  те  ла; ан  ти-C1q ан  ти  те  ла; лу-
пу  сни не  фри  тис; SLE­DAI
Анти-dsDNA, антинуклеозомска и анти-C1q антитела као показатељи 
активности болести код особа са системским еритемским лупусом
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